List of Zegalogue drug patents
Zegalogue is owned by Zealand Pharma.
Zegalogue contains Dasiglucagon Hydrochloride.
Zegalogue has a total of 1 drug patent out of which 0 drug patents have expired.
Zegalogue was authorised for market use on 22 March, 2021.
Zegalogue is available in solution;subcutaneous dosage forms.
Drug patent challenges can be filed against Zegalogue from March, 2025.
The generics of Zegalogue are possible to be released after 03 February, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10442847 | ZEALAND PHARMA | Glucagon analogues |
Feb, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic